PMID- 29996303
OWN - NLM
STAT- MEDLINE
DCOM- 20190228
LR  - 20190228
IS  - 0253-9624 (Print)
IS  - 0253-9624 (Linking)
VI  - 52
IP  - 7
DP  - 2018 Jul 6
TI  - [Economic evaluation and prediction of hepatitis B immunization strategy in 
      Shenzhen, China].
PG  - 743-747
LID - 10.3760/cma.j.issn.0253-9624.2018.07.012 [doi]
AB  - Objective: To verify the costs, benefit and effectiveness of hepatitis B 
      immunoprophylaxis strategies in Shenzhen during 2006-2030. Methods: The markov 
      model was constructed to reflect the reality of the newborn vaccination and 
      prevention of mother to child transmission (PMTCT) strategy, the cost, benefit 
      and effectiveness during 2006-2015 and 2016-2030 was evaluated and predicted by 
      the model. The model was constructed with the basic parameters such as the 
      positive rate of hepatitis B surface antibody, perinatal HBV infection rate, the 
      screening rate and positive rate of HBsAg of pregnant women, the utility value of 
      hepatitis B and the parameters of markov model. and the coverage rates, 
      vaccination fee of hepatitis B and the expenditures of patients with HB-related 
      diseases.The costs were calculated from the payer, medical-care and all society 
      perspective. The effectiveness and benefits of the strategy were evaluated and 
      predicted by the numbers of HBV infection and the patients with HBV-related 
      diseases prevented, life years (LYs), quality adjusted life years (QALYs), the 
      net benefits (NBs) and benefit cost ratio (BCRs). Results: From the payer, 
      medical-care and all society perspectives, the costs for the strategy were 153 
      million Yuan, 5.51 billion Yuan and 10.92 billion Yuan, respectively from 2006 to 
      2030 of which the forecast costs for 2016-2030 were 120 million Yuan, 3.87 
      billion yuan and 7.81 billion yuan. During the year 2006-2030, the numbers of HBV 
      infection and the HBV-related diseases was 2.48 million, more than 1.335 million 
      LYs and 1.619 million QALYs should be obtained from the strategy implemented. 
      From medical-care and all society perspectives, NBs should be 88.68 billion yuan 
      and 150.13 billion yuan with the BCRs of 17.08 and 14.75, respectively. 
      Particularly, the NBs value of 22.37 billion yuan and 37.98 billion yuan and the 
      BCR value of 14.62 and 13.20 was calculated for the past period, but the future 
      NBs of 66.31 billion yuan and 112.15 billion yuan and BCR of 18.12 and 15.36 in 
      the year 2016-2030. The further benefits were increased evidently in the future. 
      Conclusion: The hepatitis B immunization in Shenzhen has a high economic 
      effectivenee and benefits, and it is worth to invest sustainably.
FAU - Sun, P P
AU  - Sun PP
AD  - Shenzhen Center for Disease Control and Prevention, Shenzhen 518055, China.
FAU - Zhang, S X
AU  - Zhang SX
FAU - Xia, Y
AU  - Xia Y
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Yu Fang Yi Xue Za Zhi
JT  - Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
JID - 7904962
RN  - 0 (Hepatitis B Vaccines)
SB  - IM
MH  - China
MH  - Cost-Benefit Analysis
MH  - Female
MH  - Hepatitis B/*economics/*prevention & control/transmission
MH  - Hepatitis B Vaccines/*administration & dosage/*economics
MH  - Humans
MH  - Infant, Newborn
MH  - Infectious Disease Transmission, Vertical/prevention & control
MH  - Markov Chains
MH  - Pregnancy
OTO - NOTNLM
OT  - Cost-benefit
OT  - Cost-effectiveness
OT  - Forecasting
OT  - Hepatitis B
OT  - Immunization programs
EDAT- 2018/07/13 06:00
MHDA- 2019/03/01 06:00
CRDT- 2018/07/12 06:00
PHST- 2018/07/12 06:00 [entrez]
PHST- 2018/07/13 06:00 [pubmed]
PHST- 2019/03/01 06:00 [medline]
AID - 10.3760/cma.j.issn.0253-9624.2018.07.012 [doi]
PST - ppublish
SO  - Zhonghua Yu Fang Yi Xue Za Zhi. 2018 Jul 6;52(7):743-747. doi: 
      10.3760/cma.j.issn.0253-9624.2018.07.012.